Suppr超能文献

癌症疫苗:一篇批判性综述——第一部分

Cancer vaccines, a critical review--Part I.

作者信息

Mitchell Malcolm S

机构信息

Karmanos Cancer Institute, Detroit, MI 48201, USA.

出版信息

Curr Opin Investig Drugs. 2002 Jan;3(1):140-9.

Abstract

Cancer vaccines are more properly referred to as 'active specific immunotherapy', and are used to treat cancers rather than to prevent them, at least at present. Vaccines augment already established tumor immunity, are far more specific against the tumor than cytokines, have little or no toxicity, and thus may easily be combined with other types of immunotherapy. They also elicit immunological memory, which may check recurrence of the tumor. Melanoma vaccines have received the most attention thus far. Among the several vaccines in clinical trials are whole cell lysates, such as Melacine, hapten-treated autologous melanoma cells (M-Vax) and irradiated allogeneic cells (CancerVax). Regressions of metastatic nodules have been noted with each preparation. Controlled trials of Melacine indicate prolongation of survival in patients with resected stage IIB disease, particularly those with one or more of the following HLA class I alleles: HLA-A2 or -A28 (-A6802), HLA-B12, -44 or -45, and HLA-C3. A combination of interferon-alpha2b and Melacine appears to enhance the anti-tumor response in advanced (stage IV) disease, and is being tested in a large randomized controlled trial in resected stage III disease. An irradiated autologous colon carcinoma vaccine has improved relapse-free survival in resected stage II disease (Dukes B) in a controlled trial. Second-generation whole cell vaccines include those incorporating genes such as GM-CSF or CD80 (B7-1) to improve immunogenicity, and the use of immunogenic cell membranes such as large multivalent immunogen (LMI). Upregulation of HLA class II molecules and concomitant inhibition of the Ii molecule are also being explored as a strategyfor improved presentation of tumor-associated antigens in vaccines. Complex whole cell-derived vaccines have given clinically superior responses compared to vaccines containing well-defined antigens, such as peptides or gangliosides; however, well-defined vaccines are theoretically more desirable because of their reproducibility.

摘要

癌症疫苗更确切地应称为“主动特异性免疫疗法”,至少目前是用于治疗癌症而非预防癌症。疫苗可增强已建立的肿瘤免疫力,比细胞因子对肿瘤的特异性更强,毒性很小或没有毒性,因此可轻易与其他类型的免疫疗法联合使用。它们还能引发免疫记忆,这可能抑制肿瘤复发。黑色素瘤疫苗是目前受到关注最多的。在几项临床试验疫苗中,有全细胞裂解物,如Melacine、经半抗原处理的自体黑色素瘤细胞(M-Vax)和经照射的同种异体细胞(CancerVax)。每种制剂都观察到转移性结节的消退。Melacine的对照试验表明,IIB期切除术后患者的生存期延长,尤其是那些具有以下一种或多种HLA I类等位基因的患者:HLA-A2或-A28(-A6802)、HLA-B12、-44或-45,以及HLA-C3。α-干扰素2b与Melacine联合使用似乎可增强晚期(IV期)疾病的抗肿瘤反应,目前正在一项针对III期切除术后疾病的大型随机对照试验中进行测试。一种经照射的自体结肠癌疫苗在对照试验中提高了II期(Dukes B期)切除术后疾病的无复发生存期。第二代全细胞疫苗包括那些整合了GM-CSF或CD80(B7-1)等基因以提高免疫原性的疫苗,以及使用大分子量多价免疫原(LMI)等免疫原性细胞膜。上调HLA II类分子并同时抑制Ii分子也正在作为一种策略进行探索,以改善疫苗中肿瘤相关抗原的呈递。与含有明确抗原(如肽或神经节苷脂)的疫苗相比,复杂的全细胞衍生疫苗已产生临床上更好的反应;然而,从理论上讲,明确的疫苗因其可重复性而更具优势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验